Release Date: 31/07/18 11:33 Summary: Appendix 4C - June 2018 Quarter Statement of Cashflows Price Sensitive: Yes Download Document 56.91KB Download
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status